Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Northwest Biotherapeutics (NWBO) over the last 12 years, with Sep 2025 value amounting to $202,000.

  • Northwest Biotherapeutics' Capital Expenditures rose 14.77% to $202,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $677,000, marking a year-over-year decrease of 50.00%. This contributed to the annual value of $1.0 million for FY2024, which is 70.50% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Capital Expenditures stood at $202,000, which was down 33.55% from $304,000 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Capital Expenditures ranged from a high of $2.7 million in Q3 2021 and a low of $58,000 during Q1 2022.
  • Moreover, its 3-year median value for Capital Expenditures was $304,000 (2025), whereas its average is $459,091.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 89.74% in 2022, then soared by 2,198.28% in 2023.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Capital Expenditures stood at $1.6 million in 2021, then surged by 39.09% to $2.2 million in 2022, then tumbled by 80.65% to $418,000 in 2023, then crashed by 81.34% to $78,000 in 2024, then climbed by 14.77% to $202,000 in 2025.
  • Its Capital Expenditures was $202,000 in Q3 2025, compared to $304,000 in Q2 2025 and $93,000 in Q1 2025.